Understanding the Canadian patent protection and regulatory landscape The compound patent for semaglutide CA 2,601,784 was filed on March 20, 2006
Jones said she takes a GLP-1 medication that was prescribed to help manage her cholesterol
Nausea was the primary adverse event, occurring in 67% of participants at the highest dose but predominantly mild-to-moderate in severity
Exposure to light, particularly UV light, triggers photodegradation that breaks down the peptide structure
Methods Leveraging the target trial emulation framework, we conducted a retrospective study using observational data to emulate a new user, active comparator trial examining the effects of initiating GLP-1RA (exposure group) versus SGLT2 inhibitors (control group), with random treatment assignment emulated by propensity score matching with 1:1 ratio